SUMMARY This study compares the effect of epidermal growth factor and prostaglandins (PGE2 or PGI2), applied topically to gastric mucosa, on gastric secretion and formation of ASA-induced gastric ulcerations in rats. Epidermal growth factor given topically in non-antisecretory doses prevented dose-dependently the formation of ASA-induced ulcers without affecting prostaglandin generation but with a significant rise in DNA synthesis in the oxyntic mucosa. The anti-ulcer effect of topical prostaglandins was also accompanied by an increase in DNA synthesis. This study indicates that topical epidermal growth factor, like PGE2 or PGI2, is cytoprotective and that this cytoprotection is not mediated by the inhibition of gastric secretion or prostaglandin formation but related to the increase in DNA synthesis in oxyntic mucosa.
Epidermal growth factor (EGF) is a single chain of 53 amino acid residues which inhibits gastric acid secretion and stimulates epithelial cell proliferation.1 2 A hypothetical role for EGF is protection of the gastrointestinal mucosa, as it is produced by salivary and duodenal glands3 and may be secreted into the gut lumen. So far only prostaglandins (PGs) have been thought to be capable of protecting the mucosa against chemical or thermal injuty and this property, termed'cytoprotection', has been regarded as a unique feature of PGs.4 5 This study was designed to compare the gastric secretory and cytoprotective effects of EGF and PGs applied topically to the gastric mucosa against aspirin-(ASA) induced mucosal lesions and to elucidate the possible role of PG formation and DNA synthesis in the action of EGF on gastric mucosa.
Methods
Wistar rats, weighing 150-200 g, were used for the studies on gastric secretion, gastric ulcer production, *Address for correspondence: Professor SJ Konturek, Institute of Physiology, Poland. Received for publication 7 May 1981 prostaglandin generation, and DNA synthesis in the oxyntic mucosa.
SECRETORY STUDIES
Ten rats were prepared with chronic gastric fistulae, as described by Lane and Ivy, 6 and used for the secretory studies. Experiments started about one month after surgery. Rats were allowed only water for at least 24 hours and were kept in individual metabolic cages to prevent coprophagia. In the morning, animals were placed in restraining Bollman cages, the gastric fistula was opened, and the stomach washed out with tap-water. The tests were conducted with seven to 10 day intervals between successive experiments on the same animal. Gastric secretion was collected at half-hourly intervals in the graduated tubes, the volume was noted, and hydrogen ion concentration was determined by titration to pH 7 0 with 0-1 N NaOH using an automatic titrator (Radiometer, Copenhagen) and ion output was expressed in mmol/30 min. Pepsin content was also measured in each sample using Anson's haemoglobin method7 and expressed in mg/30 min.
Two series of secretory studies were performed, one under basal conditions and another after pentagastrin stimulation. Basal gastric secretion 927 Kontitrek, Brzo:owt'ski, Piastiucki, Demtibitiski, Raleeki, Demnbinska-Kiec, Zmudl(ta, atnd GIegoly was collected during three 30 minute periods and then EGF, PGE.,, or PG1., was instilled into the stomach in a dose of 100 jig/kg and the gastricfistula was closed for 25 minutes. After this interruption, the fistula was opened again, the stomach drained for five minutes, and this collection discarded. The collection was then continued for another 90 minutes with saline infused subcutaneously at a rate of 4 ml h throughout. In another series of tests, pentagastrin was infused subcutaneously at a rate of 200 pjg1kg per h throughout the experiment. The collection of gastric juice and the administration of EGF, PGE., or PGI., was similar to the tests with basal secretion. All secretory tests were performed on the same 10 gastric fistula rats.
PRODUCTION OF GASTRIC ULCERS
Gastric mucosal lesions were produced by intragastric instillation of aspirin (ASA) plus 0 15 M HCI as described by Kauffman and Grossman., For this purpose, rats were surgically prepared with a polyethylene tube in the stomach about two hours before the experiment. The intragastric instillation of ASA as a bolus injection of 60 mg kg was followed by a constant infusion of 42 mg kg/h for three hours. A simultaneous gastric perfusion with 0 15 M HCI was carried out at a rate of 4 ml h. In tests with epidermal growth factor or prostaglandins, the solution of these compounds was injected intragastrically 30 minutes before and continued throughout ASA administration. At the end of the experiment, the animals were killed, the stomach was removed and opened along the greater curvatuLre. The mucosa was quickly examined, the surface area of ulcers was measured planimetrically (mm2) and the mucosal biopsy samples were taken for determinations of PG and DNA.
Studies were perfornied on groups of eight to 30 rats, fasted 24 hours, and given one of the following intragastric treatments: (I) saline (control); (2) epidermal growth factor; (3) PGE.,; (4) PGIL; (5) ASA+HCI; (6) ASA HCI EGF; (7) ASA-HCI PGE.,; and (8) ASA-HCI PGL. As the animals receiving combinations 1-4 did not show ulceration, their stomachs were used only for the prostaglandin generation and DNA synthesis. In rats with five to eight treatments the mean ulcer area was also measured.
Solutions of epidermal growth factor and prostaglandins were freshly prepared before the experiment. EGF or PGE., was dissolved in saline and kept at room temperature, whereas PG., was dissolved in isotonic Tris buffer (pH 9 6) and kept in ice throughout the infusion. Epidermal growth factor was isolated from mouse submaxillary glands according to the method of Savage and Cohen" with minor modifications. The product, a single peak on Bio Gel P-6, had a correct amino acid ratio and was homogenieous on acrylamide gel electrophoresis. It strongly inhibited histamine stimulated acid secretion from the dog Heidenhain pouch and was equipotent with highly purified urogastrone. Both prostaglandins were a gift from Dr J Griffith of Upjohn Co (Kalamazoo, Michigan). Epidermal growth factor was given in a bolus intragastric injection of 1, 10, or 100 ug'kg and then infused intragastrically in a supporting, 10 times smaller dose (0-1, 1, or 10 ug/kg/h respectively) for 3 5 hours either alone or in combination with acidified ASA added to the infusion 30 Fig. 1.) Konturek, Brzozowski, Piastucki, Dembinski, Radecki, Dembinska-Kiec, Zmlda, and Gregolry
EFFECTS OF EGF AND PGS ON GASTRIC ULCER FORMATION, PG GENERATION, AND DNA SYNTHESIS IN ASA-TREATED RATS
All 30 control rats treated with intragastric instillation of ASA plus HC1 developed gastric ulcers that occurred mainly in the oxyntic gland areathe mean ulcer area was 7 65±0 91 mm2 (Fig. 5) (Fig. 3) . significantly raised DNA synthesis in the gastric mucosa to a level similar to that observed in control animals.
Plasma salicylate levels in rats receiving only intragastric ASA plus HC1 averaged 396±47 gig/ml and it was not significantly different in animals receiving epidermal growth factor or prostaglandins. These data are not included for the sake of clarity.
Discussion
The results show that epidermal growth factor is capable of preventing ASA-induced gastric ulcerations and the effect is not related to inhibition of gastric secretion or prostaglandin generation but to DNA synthesis in oxyntic mucosa.
The formation of gastric lesions has been attributed to a mucosal deficiency of prostaglandins because of the known irreversible inactivation of tlhe PG synthetase system by ASA.'7 This notion is supported by our findings that ASA almost completely suppresses the generation of prostaglandins in oxyntic mucosa and that PGE2 and PGI1, which are the major products of the biotransformation of arachidonate via the cyclo-oxygenase pathway in the rat gastric mucosa,'8 are capable of preventing the development of ASA-induced ulcers.4 5 18 The protective effects of exogenous PGE , and PGI., against ASA-induced mucosal lesions could be explained by the replenishment of the mucosal level of these compounds. Thus, normal generation of mucosal PGE, and PGI, appears essential for the protection of gastric mucosa against chemical injury by ASA.18 This action of prostaglandins does not appear to be mediated through the inhibition of gastric secretion (cytoprotection) as natural prostaglandins were used topically and these were found to be without any influence on basal or pentagastrin-induced gastric acid or pepsin secretion.
Although gastric cytoprotection was claimed to be a unique property of prostaglandins,4 our study provides evidence that epidermal growth factor is also cytoprotective when applied topically in a dose which does not affect gastric secretion. It appears that topical EGF neither affects the prostaglandin generation in the intact mucosa nor prevents the suppression of this generation in ASA-treated animals. This rules out the possible mediation of mucosal prostaglandins in the cytoprotective action of EGF.
The major finding is that pretreatment with acidified ASA decreases DNA synthesis with gastric ulceration and EGF reverses this change in DNA synthesis. The reason for the reduction in DNA synthesis by ASA is unknown but it may be due to destruction of large numbers of mucosal cells, possibly because of the removal by ASA of the cytoprotective function of mucosal prostaglandins. Indeed, topical administration of exogenous prostaglandins in a non-antisecretory dose prevents the fall in DNA synthesis while protecting the mucosa against ulcer formation. Thus, the common action of both epidermal growth factor and prostaglandins is the prevention of DNA synthesis which renders the oxyntic mucosa more resistant to the ulcerogenic effect of acidified ASA.
It may be worthwhile to mention that a similar reduction in DNA synthesis in the gastric mucosa of animals with stress-induced gastric ulcerations has been reported.'9 20 The application of trophic substances such as growth hormone19 or pentagastrin20 prevented the formation of these lesions and this effect was also closely correlated with an increase in DNA synthesis.
This study demonstrates that epidermal growth factor is cytoprotective after topical application to the gastric mucosa when the inhibitory effect of the peptides is entirely excluded. This indicates that the antisecretory and growth-promoting actions of EGF are two independent features of this peptide. As EGF is produced by the salivary and duodenal glands and may be released into the gut lumen, it may serve as a natural growth-promoting factor for the mucosa, and is also responsible for its protection against injury by various noxious agents. Thus, the gastrointestinal mucosa is provided with at least two separate cytoprotective mechanisms, one related to the local generation of prostaglandins and another involving the release and action of epidermal growth factot. 
